The title of the NOX presentation at ASCO is:
A phase 1 study of NOX66 in combination with carboplatin in patients with end stage cancer
Graham Kelly appears to think that the use of NOX66 plus chemotherapy has considerable commercial potential, but what would he know?
We should find out just why he remains confident when the updated abstract is published on the Noxopharm website on its day of presentation.
- Forums
- ASX - By Stock
- NOX
- ASCO
NOX
noxopharm limited
Add to My Watchlist
2.11%
!
9.3¢

ASCO
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.3¢ |
Change
-0.002(2.11%) |
Mkt cap ! $27.17M |
Open | High | Low | Value | Volume |
9.4¢ | 9.4¢ | 9.3¢ | $5.033K | 54.05K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 5398 | 9.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.4¢ | 151194 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 5398 | 0.092 |
1 | 10989 | 0.091 |
3 | 66454 | 0.090 |
1 | 57000 | 0.089 |
1 | 11764 | 0.085 |
Price($) | Vol. | No. |
---|---|---|
0.094 | 151194 | 1 |
0.095 | 7855 | 1 |
0.098 | 2048 | 1 |
0.099 | 90000 | 1 |
0.100 | 47999 | 2 |
Last trade - 11.31am 16/09/2025 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
FBM
FUTURE BATTERY MINERALS LIMITED
Nick Rathjen, MD & CEO
Nick Rathjen
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online